Core Insights - Plus Therapeutics Inc. (NASDAQ:PSTV) experienced a significant stock price increase of 39.29% on Thursday, closing at $0.5630, following a national coverage agreement with UnitedHealth Group Inc. [1] Group 1: Partnership and Market Impact - The partnership allows Plus Therapeutics, through its subsidiary CNSide Diagnostics LLC, to provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed tests (LDT) to over 51 million people in the US [2] - This agreement is expected to lead to increased revenues for both CNSide and Plus Therapeutics [3] Group 2: Product Performance and Efficacy - Since 2020, over 11,000 CNSide tests have been conducted at more than 120,000 cancer institutions, achieving a high sensitivity of 92% and specificity of 95%, while influencing treatment decisions in 90% of cases [4]